With OTC Cialis Rights, Sanofi Launches Latest Salvo In Consumer Sector Battle
This article was originally published in The Tan Sheet
Sanofi gains rights from Eli Lilly & Co. to apply for OTC approval of Cialis in the U.S., Europe, Canada and Australia. Launching the first OTC product indicated for erectile dysfunction would mark another milestone in Sanofi CEO Chris Viebacher’s mission to move the firm into the neighborhood of global OTC leaders.
You may also be interested in...
Germany's Ministry of Health surprised all those present at a recent BAH meeting by announcing it would like to see erectile dysfunction drugs like sildenafil and tadalafil available OTC. Such a move, however, would put the government at odds with drug regulator BfArM's Expert Committee for Prescription, which recently rejected an application for the Rx-to-OTC switch of sildenafil.
Merck consumer slips; Sanofi touts diversity; Bayer’s eye on the prize; incentives, China slow USANA growth; Ukraine changes cost Mannatech; vitamins strengthen Church & Dwight.
Patent settlement will enable Teva to enter the market more than three years before Viagra’s use patent expires; Pfizer suddenly parts ways with General Counsel Amy Schulman.